Of note, TIGIT (58), PDCD1 (59), HAVCR2 (60), CTLA4 (61) and BTLA (62) expression were reported to be predictive for favorable prognosis and immunotherapy response in melanoma. This evidence concerns the gene CTLA4 and melanoma.